About three years ago I had a meeting in Seattle with a company that felt they were on the verge of a breakthrough in treating depression and Parkinson's disease. They had terrific results in their clinical trials. They just needed to raise another round of financing to be able to finish their clinical studies and have something with which to go to market. They are no longer with us. Why? I don't really know.At the time, one of the key diagnostic measures, the fMRI, was not fully embraced by the clinical community. But, my oh my, things have changed for neuromodulation as a treatment modality.
The race is on to decide who will dominate the market. It looks like Medtronic has the lead. Here is a tidbit about the current (no pun intended) state of affairs.